HistoSonics is a medical device company developing a non-invasive robotic platform and novel beam therapy, Robotically Assisted Sonic Therapy (RASTSM). RAST uses the science of histotripsy and the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company's new platform delivers personalized, tissue-specific treatments with unparalleled precision and control, and without the undesirable side effects of many of today's interventional and surgical modalities. Histotripsy was developed at the University of Michigan and exclusively licensed to HistoSonics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/19 | $54,000,000 | Series C |
Johnson & Johnson Innovation Lumira Ventures State of Wisconsin Investment Board Varian Medical Systems  Venture Investors | undisclosed |
